医学
前列腺癌
放射性配体
谷氨酸羧肽酶Ⅱ
前列腺
肿瘤科
抗原
内科学
阉割
泌尿科
前列腺特异性抗原
癌症
受体
免疫学
激素
作者
Wolfgang Roll,Axel Bräuer,Matthias Weckesser,Martin Bögemann,Kambiz Rahbar
标识
DOI:10.1097/rlu.0000000000002212
摘要
Radiolabeled ligands targeting prostate-specific membrane antigen (PSMA) are currently being established. Prostate-specific membrane antigen radioligand therapy with Lu-PSMA-617 is a promising treatment in metastasized castration-resistant prostate cancer with high efficacy and safety and seems to prolong progression-free survival and overall survival. We present Ga-PSMA PET/CT images during and after 2 therapy courses, including each 4 cycles of Lu-PSMA-617, and prostate-specific antigen-level history of a 77-year-old heavily pretreated patient with metastasized castration-resistant prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI